Trial reportPloS one2021
Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01040910 (A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review.Journal of cannabis research · 2026Pooled it
- Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Pooled it
- The impact of cannabis on immune checkpoint inhibitor therapy: a systematic review of immunomodulatory effects of cannabis in patients with and without cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption.Frontiers in endocrinology · 2021Trial
- CB2R promotes T cell gut homing and exacerbates ileitis in a murine Crohn's model.Inflammatory bowel diseases · 2026Article
- Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review.Drug and alcohol review · 2026Review
- A novel enema formulation containing cannabidiol and sodium propionate for ulcerative colitis: preclinical assessment in a murine model.Journal of cannabis research · 2026Article
- Efficacy of cannabis oil on appetite and quality of life in systemic sclerosis patients: a randomized placebo-controlled trial.Journal of cannabis research · 2025Article
- Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD.Current gastroenterology reports · 2025Review
- Inflammatory bowel disease patients believe cannabis and cannabidiol oil relieve symptoms.Academia medicine · 2025Article
- Emerging Natural Therapies for the Treatment of Inflammatory Bowel Disease.Current pharmaceutical biotechnology · 2025Review
- Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes.Cannabis (Albuquerque, N.M.) · 2025Article
- Medicinal Cannabis and the Intestinal Microbiome.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Inflammatory biomarkers and psychological variables to assess quality of life in patients with inflammatory bowel disease: a cross-sectional study.Annals of medicine · 2024Article
- The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective.Cureus · 2024Review
- The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacological reviews · 2024Review
- Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada.Crohn's & colitis 360 · 2024Article
- Cannabinoids and the Gastrointestinal Tract.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Review
- Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases.International journal of molecular sciences · 2023Review
- Cannabis Improves Clinical Outcomes and Quality of Life in Patients With Chronic Pouchitis.ACG case reports journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients.
methodsIn a double-blind, randomized, placebo-controlled trial, patients received either cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes for 8 weeks. Parameters of disease including Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL) were assessed before, during and after treatment.
resultsThe study included 32 patients. Mean age was 30 years, 14 (43%) females. Lichtiger index improved in the cannabis group from 10.9 (IQR 9-14) to5 (IQR 1-7), (p<0.000), and in the placebo group from 11 (IQR 9-13) to 8 (IQR 7-10)(p = 0.15, p between groups 0.001). QOL improved in the cannabis group from 77±4 to 98±20 (p = 0.000) but not in the placebo group (78±3 at week 0 and 78±17 at week 8;p = 0.459; p between groups 0.007). Mayo endoscopic score changed in the cannabis group from 2.13±1 to 1.25±2 (p = 0.015) and in the placebo group from 2.15±1to 1.69±1 (p = 0.367, p between groups 0.17).
conclusionShort term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. However, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.(clinicaltrials.gov NCT01040910).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.